Sonnet BioTherapeutics (SONN) News Today $1.54 0.00 (0.00%) As of 01/21/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Sonnet BioTherapeutics expands Phase 1 SB101 trialJanuary 21 at 10:36 PM | markets.businessinsider.comSonnet BioTherapeutics begins trial combining SON-1010, trabectedinJanuary 21 at 12:35 PM | msn.comSonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain SarcomasJanuary 21 at 9:05 AM | globenewswire.comSonnet BioTherapeutics Announces Release of the Next CEO Corner SegmentDecember 23, 2024 | globenewswire.comSonnet BioTherapeutics sees cash runway into July 2025December 18, 2024 | markets.businessinsider.comSonnet BioTherapeutics reports FY24 EPS ($11.35) vs. ($145.13) last yearDecember 17, 2024 | markets.businessinsider.comInsights into Sonnet BioTherapeutics Q4 EarningsDecember 17, 2024 | benzinga.comSonnet BioTherapeutics Reports Fiscal Year 2024 Financial Results and Provides Corporate UpdateDecember 17, 2024 | globenewswire.comSonnet announces safety data following SON-1010 monotherapy dose escalationDecember 10, 2024 | markets.businessinsider.comSonnet BioTherapeutics announces $3.9M registered direct offeringDecember 9, 2024 | markets.businessinsider.comSonnet BioTherapeutics Announces Positive Topline Safety Data Of SON-1010 At Highest Dose, Stock UpDecember 9, 2024 | markets.businessinsider.comSonnet BioTherapeutics Announces $3.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq RulesDecember 9, 2024 | globenewswire.comSonnet BioTherapeutics Announces Topline Safety Data Following Successful Completion of SON-1010 Monotherapy Dose Escalation in Phase 1 SB101 TrialDecember 9, 2024 | globenewswire.comSonnet BioTherapeutics Reports Promising Data for SON-1010December 5, 2024 | markets.businessinsider.comSonnet BioTherapeutics announces publication on SON-1010 developmentDecember 5, 2024 | markets.businessinsider.comSonnet BioTherapeutics Announces Publication Detailing the Discovery and Development of SON-1010, an Albumin-Binding IL-12 Fusion Protein, Demonstrating Its Mechanism of ActionDecember 4, 2024 | globenewswire.comSonnet BioTherapeutics releases ‘What this Means’ segmentNovember 13, 2024 | markets.businessinsider.comSonnet BioTherapeutics Releases Virtual Investor ‘”What this Means” SegmentNovember 12, 2024 | globenewswire.comSonnet BioTherapeutics secures US patent covering two drug candidatesNovember 8, 2024 | finance.yahoo.comSonnet BioTherapeutics prices $5M at-the-market offeringNovember 7, 2024 | markets.businessinsider.comSonnet BioTherapeutics (NASDAQ:SONN) Stock Quotes, Forecast and News SummaryNovember 6, 2024 | benzinga.comSonnet BioTherapeutics Announces Issuance of U.S. Patent Covering a Variant IL-18 Incorporated into Two Novel Immunotherapeutic Drug CandidatesNovember 6, 2024 | globenewswire.comSonnet BioTherapeutics Inc. Regains Compliance with NasdaqOctober 17, 2024 | globenewswire.comSonnet BioTherapeutics’ Strategic Deal to Develop DPN TreatmentOctober 10, 2024 | finance.yahoo.comSonnet Partners Alkem To Develop And Market SON-080 For Diabetic Peripheral Neuropathy In IndiaOctober 10, 2024 | markets.businessinsider.comSonnet BioTherapeutics Inc. Enters into Licensing Agreement with Alkem Laboratories Limited to Develop and Commercialize SON-080 for Diabetic Peripheral Neuropathy (DPN) in IndiaOctober 9, 2024 | globenewswire.comSonnet BioTherapeutics secures tax credit approvalOctober 6, 2024 | investing.comSonnet BioTherapeutics to Receive Non-Dilutive Funding Through New Jersey Tax Certificate Transfer and Australia R&D Tax Incentive ProgramsOctober 4, 2024 | globenewswire.comSonnet BioTherapeutics Announces Launch of CEO Corner PlatformSeptember 30, 2024 | globenewswire.comSonnet BioTherapeutics To Effect 1-for-8 Reverse Stock SplitSeptember 25, 2024 | markets.businessinsider.comWhy Sonnet BioTherapeutics (SONN) Shares Are Down 19% TodaySeptember 25, 2024 | msn.comSonnet BioTherapeutics Announces 1-for-8 Reverse Stock SplitSeptember 25, 2024 | globenewswire.comSonnet BioTherapeutics Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid TumorsSeptember 18, 2024 | globenewswire.comSonnet BioTherapeutics to Participate in the Virtual Investor Closing Bell SeriesSeptember 4, 2024 | globenewswire.comSonnet BioTherapeutics Holdings, Inc. (SONN)August 27, 2024 | finance.yahoo.comAnalysts’ Top Healthcare Picks: Sonnet BioTherapeutics Holdings (SONN), Agilent (A)August 26, 2024 | markets.businessinsider.comSonnet BioTherapeutics Enters into Clinical Collaboration Agreement to Commence Investigator-Initiated and Funded Phase 1/2a Study of SON-1210 in Combination with Chemotherapy for the Treatment of Pancreatic CancerAugust 19, 2024 | globenewswire.comSonnet BioTherapeutics Holdings, Inc.: Sonnet BioTherapeutics Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate UpdateAugust 16, 2024 | finanznachrichten.deSONN Stock Earnings: Sonnet BioTherapeutics Beats EPS for Q3 2024August 14, 2024 | investorplace.comSonnet BioTherapeutics Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate UpdateAugust 14, 2024 | globenewswire.comJTC Team, LLC: Sonnet BioTherapeutics Participates in Virtual Investor "What This Means" Segment Hosted by JTC TeamJuly 25, 2024 | finanznachrichten.deSonnet BioTherapeutics Reports Encouraging Data from Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) That Support Advancement into Phase 2 StudyJuly 24, 2024 | globenewswire.comSonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual MeetingMay 28, 2024 | globenewswire.comSonnet BioTherapeutics, Inc.: Sonnet BioTherapeutics Announces Review of Strategic AlternativesMay 22, 2024 | finanznachrichten.deSonnet BioTherapeutics Announces Review of Strategic AlternativesMay 22, 2024 | finance.yahoo.comSONN Stock Earnings: Sonnet BioTherapeutics Misses EPS for Q2 2024May 15, 2024 | investorplace.comAnalysts Offer Insights on Healthcare Companies: Cullinan Management (CGEM) and HCA Healthcare (HCA)April 28, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Legend Biotech (LEGN), Genmab (GMAB)April 17, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Bausch Health Companies (BHC) and Arcus Biosciences (RCUS)April 12, 2024 | markets.businessinsider.comSonnet BioTherapeutics Announces Early Safety Data from the Company’s Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Met the Study’s Initial Pre-Specified ObjectiveMarch 11, 2024 | finance.yahoo.com Get Sonnet BioTherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SONN and its competitors with MarketBeat's FREE daily newsletter. Email Address SONN Media Mentions By Week SONN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SONN News Sentiment▼0.000.64▲Average Medical News Sentiment SONN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SONN Articles This Week▼31▲SONN Articles Average Week Get Sonnet BioTherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SONN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Affimed News Today Bullfrog AI News Today Carisma Therapeutics News Today Evaxion Biotech A/S News Today Finch Therapeutics Group News Today BioXcel Therapeutics News Today Synlogic News Today GlycoMimetics News Today BriaCell Therapeutics News Today NanoViricides News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SONN) was last updated on 1/22/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump currency shock imminentTrump's Quiet $1.9 Trillion Move Against the Fed A small army of Americans, with Trump's support, has launc...Stansberry Research | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sonnet BioTherapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sonnet BioTherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.